UN Targets on Health Risk Factors can Prevent 37 Million Deaths by 2025
News May 13, 2014
A new international study led by Imperial College London has estimated how achieving globally-agreed targets for six important health risks between 2010 and 2025 will reduce deaths caused by the big-four chronic diseases: cancers, diabetes, lung disease and cardiovascular disease (mainly heart disease and stroke).
Published in The Lancet the study finds that achieving the targets can prevent over 37 million deaths from these diseases by 2025. The large majority of the extra deaths will be in low-to-middle-income nations. Targets for reducing smoking and blood pressure will lead to the largest health benefits.
In 2011, the UN General Assembly agreed to reduce deaths from the big-four chronic diseases. The World Health Organization (WHO) created targets for both premature deaths from these chronic diseases and their key risk factors like smoking, alcohol use, high blood pressure and blood glucose, obesity and salt consumption. The researchers analyzed the effects of achieving these targets for risk factor on deaths from the four major chronic diseases.
The study shows that the big-four chronic diseases killed over 28 million people in 2010, a number that is projected to increase to 39 million in 2025 if no new action is taken.
If the six risk factor targets are achieved, the risk of dying prematurely from chronic diseases in 2025 will go down by 22 per cent for men and by 19 per cent for women compared to their 2010 levels. This corresponds to preventing more than 37 million deaths between 2010 and 2025, including 16 million deaths amongst those who are younger than 70 years and whose deaths are considered premature.
Senior author of the study, Professor Majid Ezzati from the MRC-PHE Centre for Environment at Imperial College London's School of Public Health said: "It is possible to achieve most of the desired reduction in deaths from chronic diseases by tackling a small number of preventable risk factors."
The current global targets include a 30 per cent reduction in smoking levels, a 10 per cent reduction in alcohol consumption and a 30 per cent reduction in salt in food.
The research found that achievement of some targets had bigger impacts than others, with reductions in smoking and blood pressure producing the greatest benefits.
If a more ambitious target of halving the levels of smoking is achieved alongside the other targets, the risk of dying prematurely from the big-four would be reduced by nearly 25 per cent in men - the desired global target - and by 20 per cent in women. This corresponds to averting nearly 43 million deaths between 2010 and 2025.
Study lead author, Dr Vasilis Kontis from Imperial College London's School of Public Health said: "Our study demonstrates that the tobacco use target should be more ambitious. Reducing the prevalence of smoking by 50 per cent by 2025 is feasible based on proven policy measures, and should become a global target to avoid millions of premature deaths."
Professor Ezzati said: "Much larger impacts will be seen in low-to-middle-income countries where 31 million deaths will be averted. High income countries are already working towards many of these targets with a range of policy measures such as tobacco and alcohol taxes, public smoking bans, and guidelines to reduce the amount of salt in food, although we still need to find ways to curb obesity and diabetes.
"Our study shows the urgent need for a greater policy push and injection of resources into low-to-middle-income countries to replicate the success stories and to avoid escalating numbers of chronic disease deaths in the poorest countries," he added.
The study also showed that the risk factor targets had different impacts depending on the disease. The greatest impact was on cardiovascular disease and chronic lung disease, with more than a 25 per cent reduction in the risk of premature death from each of these conditions. Importantly, achieving the risk factor targets will also reverse the rising tide of mortality from diabetes.
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE